BioLife Solutions, Inc. (NASDAQ:BLFS) Stock Position Lessened by Calamos Advisors LLC

Calamos Advisors LLC decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS) by 68.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 33,021 shares of the medical equipment provider’s stock after selling 70,827 shares during the quarter. Calamos Advisors LLC owned 0.07% of BioLife Solutions worth $857,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of BLFS. Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions in the third quarter worth $28,000. Quest Partners LLC bought a new position in BioLife Solutions during the third quarter valued at about $57,000. GAMMA Investing LLC boosted its stake in BioLife Solutions by 29.4% during the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares in the last quarter. Summit Global Investments bought a new position in BioLife Solutions during the third quarter valued at about $228,000. Finally, Marshall Wace LLP bought a new position in BioLife Solutions during the second quarter valued at about $229,000. Institutional investors own 93.24% of the company’s stock.

Insider Activity

In related news, CFO Troy Wichterman sold 987 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now directly owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Aby J. Mathew sold 25,000 shares of the stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $21.17, for a total value of $529,250.00. Following the completion of the sale, the executive vice president now directly owns 302,046 shares of the company’s stock, valued at approximately $6,394,313.82. This represents a 7.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 54,278 shares of company stock valued at $1,199,987 over the last three months. Insiders own 2.20% of the company’s stock.

BioLife Solutions Trading Up 1.5 %

Shares of NASDAQ BLFS opened at $26.72 on Thursday. BioLife Solutions, Inc. has a 12 month low of $14.50 and a 12 month high of $29.55. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -25.21 and a beta of 1.91. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The business has a fifty day simple moving average of $26.81 and a 200-day simple moving average of $25.16.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Craig Hallum raised their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. KeyCorp raised their target price on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. Northland Securities raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. HC Wainwright decreased their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Monday, November 18th. Finally, Benchmark reaffirmed a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.